moxifloxacin has been researched along with Conjunctivitis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Honkila, M; Ikäheimo, I; Kontiokari, T; Koskela, U; Kristo, A; Mattila, ML; Paalanne, N; Pokka, T; Renko, M; Sarlin, S; Tapiainen, T; Uhari, M; Valtonen, R | 1 |
| Chhabra, MS; Mortensen, JE; Motley, WW | 1 |
| Betanzos-Cabrera, G; Cancino-Díaz, JC; Cancino-Díaz, ME; González-González, G; Juárez-Verdayes, MA | 1 |
| Burd, EM; Sharp, SE | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 1 |
2 review(s) available for moxifloxacin and Conjunctivitis
| Article | Year |
|---|---|
Effect of Topical Antibiotics on Duration of Acute Infective Conjunctivitis in Children: A Randomized Clinical Trial and a Systematic Review and Meta-analysis.
Topics: Acute Disease; Anti-Bacterial Agents; Child; Child, Preschool; Conjunctivitis; Female; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Randomized Controlled Trials as Topic | 2022 |
[Moxifloxacin (Kanavig), ophthalmic administration].
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Aza Compounds; Conjunctivitis; Contraindications; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Quinolines | 2012 |
5 other study(ies) available for moxifloxacin and Conjunctivitis
| Article | Year |
|---|---|
Eikenella corrodens as a causative agent for neonatal conjunctivitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clavulanic Acid; Conjunctivitis; Drug Administration Schedule; Drug Therapy, Combination; Eikenella corrodens; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infant; Moxifloxacin; Ophthalmic Solutions; Quinolines; Treatment Outcome | 2008 |
Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Topics: Anti-Infective Agents; Aza Compounds; Conjunctivitis; Corneal Ulcer; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcus epidermidis | 2009 |
Photo quiz: A 36-year-old with recurrent conjunctivitis.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Aza Compounds; Bacterial Typing Techniques; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis; Corneal Transplantation; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Microscopy; Moxifloxacin; Paracoccus; Quinolines; Recurrence; Surgical Wound Infection | 2012 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Aza Compounds; Conjunctivitis; Endophthalmitis; Fluoroquinolones; Injections; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2008 |